US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
WO1996004925A1
(en)
*
|
1994-08-12 |
1996-02-22 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US5874540A
(en)
*
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
JP3904238B2
(ja)
|
1996-03-20 |
2007-04-11 |
イムノメディクス, インコーポレイテッド |
グリコシル化されたヒト化b細胞特異的抗体
|
DK0821006T3
(da)
*
|
1996-07-26 |
2004-08-16 |
Aventis Pharma Gmbh |
Insulinderivater med öget zinkbinding
|
UA76934C2
(en)
*
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
EP1007569B1
(en)
*
|
1997-02-11 |
2009-04-08 |
Immunomedics, Inc. |
Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
|
US6183744B1
(en)
*
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
AU745823B2
(en)
*
|
1997-05-02 |
2002-04-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Immunotoxins, comprising an onc protein, directed against malignant cells
|
CN101073667B
(zh)
*
|
1997-10-14 |
2013-11-06 |
中外制药株式会社 |
淋巴细胞肿瘤抗体的增强剂
|
US20010033839A1
(en)
*
|
1999-10-04 |
2001-10-25 |
Emilio Barbera-Guillem |
Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
US20030099629A1
(en)
*
|
1999-03-11 |
2003-05-29 |
Immunomedics, Inc. |
Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
|
EP2039368A3
(en)
|
1999-04-30 |
2009-04-01 |
La Jolla Institute For Allergy And Immunology |
Methods for preventing reactivation of latent virus and controlling virus replication
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
KR20020025990A
(ko)
|
1999-08-23 |
2002-04-04 |
나가야마 오사무 |
에이치엠1.24 항원의 발현 증강제
|
US7118745B1
(en)
|
1999-09-27 |
2006-10-10 |
The Regents Of The University Of California |
Engineering antibodies that bind irreversibly
|
CA2385888A1
(en)
*
|
1999-09-27 |
2001-04-05 |
The Regents Of The University Of California |
Engineering antibodies that bind irreversibly
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
AU8729101A
(en)
*
|
2000-03-31 |
2001-10-15 |
Idec Pharma Corp |
Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
|
AU2001268363B2
(en)
*
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
KR100545945B1
(ko)
*
|
2000-07-03 |
2006-01-25 |
갈라 디자인, 인크. |
발현 벡터
|
US20030224415A1
(en)
*
|
2001-06-29 |
2003-12-04 |
Gala Design, Inc. |
Selection free growth of host cells containing multiple integrating vectors
|
AU2001271614B2
(en)
*
|
2000-07-03 |
2007-05-31 |
Catalent Pharma Solutions, Llc |
Host cells containing multiple integrating vectors
|
US20040235173A1
(en)
*
|
2000-07-03 |
2004-11-25 |
Gala Design, Inc. |
Production of host cells containing multiple integrating vectors by serial transduction
|
ATE391174T1
(de)
|
2000-10-20 |
2008-04-15 |
Chugai Pharmaceutical Co Ltd |
Modifizierter tpo-agonisten antikörper
|
US7090843B1
(en)
*
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
EP1372724A2
(en)
|
2001-01-31 |
2004-01-02 |
Idec Pharmaceuticals Corporation |
Use of immunoregulatory antibodies in the treatment of neoplastic disorders
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
US20030118585A1
(en)
*
|
2001-10-17 |
2003-06-26 |
Agy Therapeutics |
Use of protein biomolecular targets in the treatment and visualization of brain tumors
|
US7321026B2
(en)
*
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
US7151164B2
(en)
|
2002-02-14 |
2006-12-19 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
KR20040094705A
(ko)
*
|
2002-02-21 |
2004-11-10 |
듀크 유니버시티 |
자가면역질환에 대한 시약 및 치료 방법
|
IL163851A0
(en)
|
2002-03-01 |
2005-12-18 |
Immunomedics Inc |
Internalizing anti-cd74 antibodies and methods of use
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
CN100360567C
(zh)
|
2002-03-01 |
2008-01-09 |
免疫医疗公司 |
Rs7抗体
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20060099142A1
(en)
*
|
2002-03-14 |
2006-05-11 |
Delaney Allen D |
Cancer associated araf1 protein kinase and its uses
|
US20040038304A1
(en)
*
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
ES2545745T3
(es)
|
2002-05-02 |
2015-09-15 |
Wyeth Holdings Llc |
Conjugados de transportador derivado de caliqueamicina
|
CN1675245B
(zh)
*
|
2002-06-14 |
2011-01-12 |
免疫医疗公司 |
人源化单克隆抗体hPAM4
|
US7238786B2
(en)
*
|
2002-06-14 |
2007-07-03 |
Immunomedics, Inc. |
Monoclonal antibody cPAM4
|
US7939304B2
(en)
*
|
2002-10-02 |
2011-05-10 |
Catalyst Biosciences, Inc. |
Mutant MT-SP1 proteases with altered substrate specificity or activity
|
US20060024289A1
(en)
*
|
2002-10-02 |
2006-02-02 |
Ruggles Sandra W |
Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
|
US8158385B2
(en)
|
2002-10-11 |
2012-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death-inducing agent
|
EP1551876B1
(en)
|
2002-10-16 |
2011-03-16 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
US7820787B2
(en)
*
|
2003-01-23 |
2010-10-26 |
The Regents Of The University Of California |
Multi-functional antibodies
|
CN1767860A
(zh)
*
|
2003-01-31 |
2006-05-03 |
免疫医疗公司 |
施用治疗和诊断剂的方法和组合物
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
WO2004087763A1
(ja)
*
|
2003-03-31 |
2004-10-14 |
Chugai Seiyaku Kabushiki Kaisha |
Cd22に対する改変抗体およびその利用
|
AU2004255216B2
(en)
*
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
US7902338B2
(en)
*
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
PL1678314T3
(pl)
|
2003-10-22 |
2013-02-28 |
Keck Graduate Inst |
Sposoby syntezy polipeptydów heteromultimerycznych w drożdżach, wykorzystujące strategię kojarzenia haploidalnego
|
BRPI0416243A
(pt)
*
|
2003-11-05 |
2007-01-09 |
Palingen Inc |
método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
|
JP4912153B2
(ja)
|
2003-12-01 |
2012-04-11 |
イミューノメディクス、インコーポレイテッド |
タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
|
WO2005056602A1
(ja)
*
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
アゴニスト活性を有する改変抗体のスクリーニング方法
|
TW200530269A
(en)
*
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
US20070280951A1
(en)
*
|
2003-12-12 |
2007-12-06 |
Naoki Kimura |
Cell Death Inducing Agents
|
TW200530266A
(en)
*
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Method of reinforcing antibody activity
|
US20050221429A1
(en)
*
|
2004-01-16 |
2005-10-06 |
Cardinal Health Pts, Llc |
Host cells containing multiple integrating vectors comprising an amplifiable marker
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
EP2423331B1
(en)
|
2004-03-31 |
2019-05-08 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
JP4799405B2
(ja)
*
|
2004-04-09 |
2011-10-26 |
中外製薬株式会社 |
細胞死誘導剤
|
EP2308967B1
(en)
|
2004-04-12 |
2017-08-23 |
Catalyst Biosciences, Inc. |
Mutant mt-sp1 polypeptides
|
MXPA06014069A
(es)
*
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Metodo para tratar esclerosis multiple.
|
MXPA06014067A
(es)
*
|
2004-06-04 |
2007-02-15 |
Genentech Inc |
Metodo para tratar lupus.
|
RU2427588C2
(ru)
*
|
2004-07-09 |
2011-08-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против глипикана 3
|
EP1781378A2
(en)
*
|
2004-07-22 |
2007-05-09 |
Genentech, Inc. |
Method of treating sjögren's syndrome
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
CA2580271A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
US7572896B2
(en)
|
2005-02-03 |
2009-08-11 |
Raven Biotechnologies, Inc. |
Antibodies to oncostatin M receptor
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
CA2599734C
(en)
*
|
2005-03-03 |
2014-01-28 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP1870458B1
(en)
|
2005-03-31 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 STRUCTURAL ISOMERS
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US20090022687A1
(en)
*
|
2005-05-18 |
2009-01-22 |
Chugai Seiyaku Kabushiki Kaisha |
Novel Pharmaceuticals That Use Anti-HLA Antibodies
|
BRPI0613259A2
(pt)
*
|
2005-05-20 |
2010-12-28 |
Genentech Inc |
método de tratamento de amostra biológica e kit de diagnóstico
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
US9241994B2
(en)
|
2005-06-10 |
2016-01-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(Fv)2
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
US20070190047A1
(en)
*
|
2005-07-29 |
2007-08-16 |
Amgen, Inc. |
Formulations that inhibit protein aggregation
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
EP2674440B1
(en)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
EP1998799B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
KR100701923B1
(ko)
|
2006-03-15 |
2007-03-30 |
주식회사 녹십자 |
항- b림프종 단일클론항체 및 이를 생산하는 하이브리도마세포주
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
CN103030696B
(zh)
*
|
2006-05-30 |
2016-09-28 |
健泰科生物技术公司 |
抗体和免疫偶联物及其用途
|
DK2046951T5
(da)
|
2006-07-05 |
2012-01-23 |
Catalyst Biosciences Inc |
Proteasesreeningsmetoder og proteaser identificeret dermed
|
BRPI0714209A2
(pt)
*
|
2006-07-13 |
2014-06-24 |
Chugai Pharmaceutical Co Ltd |
Induzidor de morte celular
|
SG177168A1
(en)
|
2006-12-01 |
2012-01-30 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
NZ577933A
(en)
|
2007-01-22 |
2011-12-22 |
Genentech Inc |
Polyelectrolyte precipitation and purification of antibodies
|
CL2008000719A1
(es)
*
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
LT2164514T
(lt)
|
2007-05-21 |
2017-03-10 |
Alderbio Holdings Llc |
Il-6 antikūnai ir jų naudojimas
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
US20110097318A1
(en)
*
|
2007-08-31 |
2011-04-28 |
Amgen Inc. |
Solid-State Protein Formulation
|
EP2205280B1
(en)
*
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
US20090169550A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
KR20110014607A
(ko)
*
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153578A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
SG192489A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
EP2318832B1
(en)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
KR20110033233A
(ko)
*
|
2008-07-21 |
2011-03-30 |
이뮤노메딕스, 인코오포레이티드 |
개선된 치료 특성을 갖는 항체의 구조 변이체
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
JP5230344B2
(ja)
*
|
2008-10-14 |
2013-07-10 |
日機装株式会社 |
熱交換装置
|
WO2010065078A1
(en)
|
2008-11-25 |
2010-06-10 |
Alder Biopharmaceuticals, Inc. |
Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
EP3903829B1
(en)
|
2009-02-13 |
2023-05-03 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
US9028833B2
(en)
|
2012-12-13 |
2015-05-12 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
NZ594514A
(en)
*
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
RU2012112550A
(ru)
*
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
US8758750B2
(en)
|
2009-09-15 |
2014-06-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic anti-CD47 therapy for hematologic cancers
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
US20110070227A1
(en)
*
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
WO2011047262A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
MX344382B
(es)
|
2009-10-23 |
2016-12-14 |
Amgen Inc * |
Adaptador de vial y sistema.
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
WO2011085354A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
US9631018B2
(en)
|
2010-03-26 |
2017-04-25 |
The Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
EP2568976B1
(en)
|
2010-05-10 |
2015-09-30 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
ES2545411T5
(es)
|
2010-06-07 |
2024-04-05 |
Amgen Inc |
Dispositivo de administración de fármaco
|
WO2011163401A2
(en)
|
2010-06-22 |
2011-12-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
ES2719624T3
(es)
|
2010-09-23 |
2019-07-11 |
Prec Biologics Inc |
Peptidomiméticos de cáncer de colon y de páncreas
|
CN104531671A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
TWI603738B
(zh)
|
2010-11-08 |
2017-11-01 |
建南德克公司 |
皮下投予抗-il-6受體抗體
|
DK2643018T3
(da)
|
2010-11-23 |
2021-01-18 |
Vitaeris Inc |
Anti-il-6-antistoffer til behandling af oral mucositis
|
US9783601B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
JP6162606B2
(ja)
|
2011-01-14 |
2017-07-12 |
レッドウッド バイオサイエンス, インコーポレイテッド |
アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
|
WO2012135315A1
(en)
|
2011-03-31 |
2012-10-04 |
Amgen Inc. |
Vial adapter and system
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
CA3145238A1
(en)
|
2011-04-20 |
2012-10-26 |
Amgen Inc. |
Autoinjector apparatus
|
CA2831572C
(en)
|
2011-05-02 |
2019-11-26 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
MX365813B
(es)
|
2011-05-20 |
2019-06-14 |
Alderbio Holdings Llc |
Uso de anticuerpos anti-cgrp o anti-cgrp o fragmentos de anticuerpo para tratar o prevenir formas crónicas y agudas de diarrea.
|
US9708393B2
(en)
|
2011-05-20 |
2017-07-18 |
Alderbio Holdings Llc |
Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
RS62628B1
(sr)
|
2011-05-20 |
2021-12-31 |
H Lundbeck As |
Proizvodnja visoke čistoće više-podjediničnih proteina kao što su antitela u preobraženim mikrobima kao što su pichia pastoris
|
CN107602700B
(zh)
|
2011-05-20 |
2021-12-17 |
H.伦德贝克公司 |
抗cgrp组合物及其用途
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
SG195082A1
(en)
|
2011-05-25 |
2013-12-30 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory disorders
|
KR101978534B1
(ko)
|
2011-08-19 |
2019-08-28 |
앨더바이오 홀딩스 엘엘씨 |
변형된 미생물 이를 테면 피치아 파스토리스(pichia pastoris)에서 다수의 아단위 단백질들, 이를 테면 항체의 고역가 및 고순도 생산을 위한 다중-복사체 전략
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3492109B1
(en)
|
2011-10-03 |
2020-03-04 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
ES2923766T3
(es)
|
2011-10-14 |
2022-09-30 |
Amgen Inc |
Inyector y método de montaje
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
WO2013090648A1
(en)
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
WO2013096455A1
(en)
|
2011-12-20 |
2013-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
MX2014008101A
(es)
|
2011-12-30 |
2014-09-25 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US8999380B2
(en)
|
2012-04-02 |
2015-04-07 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
CA2871764A1
(en)
*
|
2012-04-26 |
2013-10-31 |
Gerhard Frey |
Anti-cd22 antibodies
|
CA2874521A1
(en)
|
2012-05-24 |
2013-11-28 |
Dana-Farber Cancer Institute, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
US20150285802A1
(en)
|
2012-07-18 |
2015-10-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
IN2015DN00552A
(es)
|
2012-07-19 |
2015-06-26 |
Redwood Bioscience Inc |
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
SI2890402T1
(sl)
|
2012-08-31 |
2019-07-31 |
Sutro Biopharma, Inc. |
Modificirane aminokisline vsebujoče acido skupino
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
KR102238677B1
(ko)
|
2012-09-07 |
2021-04-12 |
코히러스 바이오사이언시즈, 인코포레이티드 |
아달리무맙의 안정한 수성 제형
|
MX364327B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
|
WO2014071074A2
(en)
|
2012-11-01 |
2014-05-08 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
CA2884887C
(en)
|
2012-11-21 |
2023-09-12 |
Amgen Inc. |
Drug delivery device including insertion member and reservoir
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
CA2896690A1
(en)
|
2012-12-21 |
2014-06-26 |
Abgenomics International Inc. |
Hydrophilic self-immolative linkers and conjugates thereof
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
|
AU2013370171B2
(en)
|
2012-12-28 |
2018-09-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
EP2968775B1
(en)
|
2013-03-15 |
2019-12-18 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
ES2973257T3
(es)
|
2013-03-15 |
2024-06-19 |
Amgen Inc |
Casete de fármaco, autoinyector y sistema de autoinyector
|
WO2014145650A1
(en)
|
2013-03-15 |
2014-09-18 |
Alder Biopharmaceuticals, Inc. |
Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2970865B1
(en)
|
2013-03-15 |
2020-09-02 |
Alder Biopharmaceuticals, Inc. |
Antibody purification and purity monitoring
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
JP6670740B2
(ja)
|
2013-03-22 |
2020-03-25 |
アムジエン・インコーポレーテツド |
注入器および組み立て法
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
TWI712419B
(zh)
|
2013-07-03 |
2020-12-11 |
美商艾爾德生物製藥股份有限公司 |
使用抗cgrp抗體之葡萄糖代謝的調節
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10130590B2
(en)
|
2013-10-01 |
2018-11-20 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer with atovaquone-related compounds
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
JP7086520B2
(ja)
|
2013-10-24 |
2022-06-20 |
アムジエン・インコーポレーテツド |
インジェクター及び組み立ての方法
|
CA3168888A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
EP3553087A1
(en)
|
2014-01-08 |
2019-10-16 |
The Board of Trustees of the Leland Stanford Junior University |
Targeted therapy for lung cancer
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
EP3107577B1
(en)
|
2014-02-21 |
2024-03-20 |
IBC Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
WO2015145360A1
(en)
|
2014-03-24 |
2015-10-01 |
Glennie Martin J |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
US10350264B2
(en)
|
2014-03-27 |
2019-07-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
|
US10865416B2
(en)
|
2014-04-17 |
2020-12-15 |
Boehringer Ingelheim Rcv Gmbh & Co Kg |
Recombinant host cell engineered to overexpress helper proteins
|
BR112016023769A2
(pt)
|
2014-04-17 |
2017-10-17 |
Boehringer Ingelheim Rcv Gmbh |
célula hospedeira recombinante para a expressão de proteínas de interesse
|
EP3785749A1
(en)
|
2014-05-07 |
2021-03-03 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
EP3141603A4
(en)
|
2014-05-08 |
2017-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
EP3149037A4
(en)
|
2014-05-27 |
2018-01-10 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカAcademia Sinica |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
EP3154582A4
(en)
|
2014-05-28 |
2018-01-10 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
SG11201609963PA
(en)
|
2014-06-03 |
2016-12-29 |
Amgen Inc |
Devices and methods for assisting a user of a drug delivery device
|
EP2952584A1
(en)
|
2014-06-04 |
2015-12-09 |
Boehringer Ingelheim RCV GmbH & Co KG |
Improved protein production
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
EP3157960A4
(en)
|
2014-06-20 |
2018-01-24 |
BioAlliance C.V. |
Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
|
JP2017523958A
(ja)
*
|
2014-06-20 |
2017-08-24 |
バイオアライアンス コマンディテール フェンノートシャップ |
抗cd22抗体−薬物コンジュゲート及びその使用方法
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016057398A1
(en)
|
2014-10-07 |
2016-04-14 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
CA2957960C
(en)
|
2014-10-14 |
2023-08-22 |
Amgen, Inc. |
Drug injection device with visual and audible indicators
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
WO2016094602A1
(en)
|
2014-12-10 |
2016-06-16 |
Tufts University |
Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016100838A2
(en)
|
2014-12-19 |
2016-06-23 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-acth antibodies and use thereof
|
JP2017538512A
(ja)
|
2014-12-19 |
2017-12-28 |
アムジエン・インコーポレーテツド |
ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
SI3656443T1
(sl)
|
2015-01-21 |
2021-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Uporaba TRL-agonista in sredtva proti CD47 za izboljšanje fagocitoze rakavih celic
|
EP3248005B1
(en)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
US10583245B2
(en)
|
2015-02-17 |
2020-03-10 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
US11806509B2
(en)
|
2015-02-27 |
2023-11-07 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
EP3313443B9
(en)
|
2015-06-25 |
2023-10-04 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US11376326B2
(en)
|
2015-07-01 |
2022-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
|
LT3334747T
(lt)
|
2015-08-13 |
2023-12-27 |
Amgen Inc. |
Įkrautas giluminis antigeną surišančio baltymo filtravimas
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
WO2017100501A1
(en)
|
2015-12-09 |
2017-06-15 |
Amgen Inc. |
Auto-injector with signaling cap
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
CN108713026B
(zh)
|
2016-01-08 |
2023-01-06 |
美国全心医药生技股份有限公司 |
四价抗psgl-1抗体及其用途
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
EP4035711A1
(en)
|
2016-03-15 |
2022-08-03 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
SG11201808632YA
(en)
|
2016-04-15 |
2018-10-30 |
Alder Biopharmaceuticals Inc |
Anti-pacap antibodies and uses thereof
|
CN109789201B
(zh)
|
2016-04-15 |
2023-06-16 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
CA3019398A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
CA3016917A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
MX2018013616A
(es)
|
2016-05-13 |
2019-02-21 |
Amgen Inc |
Montaje de cubierta protectora de vial.
|
EP3458988B1
(en)
|
2016-05-16 |
2023-10-18 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
US11098107B2
(en)
|
2016-06-15 |
2021-08-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
|
EP3478342A1
(en)
|
2016-07-01 |
2019-05-08 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
WO2018039274A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
CN114917185B
(zh)
|
2016-10-21 |
2023-11-14 |
美国安进公司 |
药物配制品及其制备方法
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
JP7252627B2
(ja)
|
2016-12-15 |
2023-04-05 |
デューク ユニバーシティ |
制御性b10細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
|
CA3049780A1
(en)
|
2017-01-17 |
2018-07-26 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
AU2018213718B2
(en)
|
2017-01-26 |
2022-08-25 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
EP3582829A1
(en)
|
2017-02-17 |
2019-12-25 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
AU2018231107B2
(en)
|
2017-03-06 |
2023-04-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
SG11201908058UA
(en)
|
2017-03-07 |
2019-09-27 |
Amgen Inc |
Needle insertion by overpressure
|
WO2018165499A1
(en)
|
2017-03-09 |
2018-09-13 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
CN114588404B
(zh)
|
2017-03-28 |
2024-07-09 |
美国安进公司 |
柱塞杆和注射器组件系统以及方法
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
JP7200134B2
(ja)
|
2017-06-08 |
2023-01-06 |
アムジエン・インコーポレーテツド |
トルク駆動式薬物送達デバイス
|
EP3634539A1
(en)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
AU2018288604B2
(en)
|
2017-06-22 |
2023-12-21 |
Amgen Inc. |
Device activation impact/shock reduction
|
EP3641861A1
(en)
|
2017-06-23 |
2020-04-29 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
WO2019014014A1
(en)
|
2017-07-14 |
2019-01-17 |
Amgen Inc. |
NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
|
WO2019018169A1
(en)
|
2017-07-21 |
2019-01-24 |
Amgen Inc. |
PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
|
MA49676A
(fr)
|
2017-07-25 |
2020-06-03 |
Amgen Inc |
Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
|
EP3658203B1
(en)
|
2017-07-25 |
2022-08-31 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
EP3664863A2
(en)
|
2017-08-09 |
2020-06-17 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
MA49897A
(fr)
|
2017-08-18 |
2020-06-24 |
Amgen Inc |
Injecteur sur-corps avec patch adhésif stérile
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
EP4257164A3
(en)
|
2017-10-06 |
2024-01-17 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
MA50348A
(fr)
|
2017-10-09 |
2020-08-19 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
|
WO2019090086A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
MA50569A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Ensembles de remplissage-finition et procédés associés
|
MA50553A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Dispositif d'administration de médicament avec détection de positionnement et de débit
|
WO2019094138A1
(en)
|
2017-11-10 |
2019-05-16 |
Amgen Inc. |
Plungers for drug delivery devices
|
AU2018368338B2
(en)
|
2017-11-16 |
2024-07-25 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
EP3826701A1
(en)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Delivery devices for administering drugs
|
WO2020023451A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
EP3829692A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
WO2020068623A1
(en)
|
2018-09-24 |
2020-04-02 |
Amgen Inc. |
Interventional dosing systems and methods
|
JP2022502403A
(ja)
|
2018-09-26 |
2022-01-11 |
アセンディス ファーマ エー/エス |
分解性ヒアルロン酸ヒドロゲル
|
WO2020068476A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
SG11202103236YA
(en)
|
2018-10-02 |
2021-04-29 |
Amgen Inc |
Injection systems for drug delivery with internal force transmission
|
AU2019355979A1
(en)
|
2018-10-05 |
2021-03-18 |
Amgen Inc. |
Drug delivery device having dose indicator
|
SG11202101824VA
(en)
|
2018-10-15 |
2021-03-30 |
Amgen Inc |
Platform assembly process for drug delivery device
|
EP3866890A1
(en)
|
2018-10-15 |
2021-08-25 |
Amgen Inc. |
Drug delivery device having damping mechanism
|
US11213620B2
(en)
|
2018-11-01 |
2022-01-04 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
AU2019370159A1
(en)
|
2018-11-01 |
2021-04-22 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
WO2020219482A1
(en)
|
2019-04-24 |
2020-10-29 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
JP2022542863A
(ja)
|
2019-07-24 |
2022-10-07 |
ハー・ルンドベック・アクチエゼルスカベット |
抗mGluR5抗体及びその使用
|
CA3148261A1
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
SG10202003296VA
(en)
|
2020-04-06 |
2021-11-29 |
H Lundbeck As |
Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
|
CA3205520A1
(en)
|
2021-02-12 |
2022-08-18 |
Richard ZAHRL |
Signal peptides for increased protein secretion
|
BR112023022133A2
(pt)
|
2021-05-07 |
2023-12-26 |
Viela Bio Inc |
Uso de um anticorpo anti-cd19 para tratar miastenia gravis
|
JPWO2022239720A1
(es)
|
2021-05-10 |
2022-11-17 |
|
|
KR20240011135A
(ko)
|
2021-05-21 |
2024-01-25 |
암젠 인크 |
약물 용기를 위한 충전 레시피를 최적화하는 방법
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング,インコーポレイテッド |
タンパク質凝集を防止する方法
|
EP4377349A1
(en)
|
2021-07-27 |
2024-06-05 |
Astrazeneca AB |
Treatment of lupus
|
CN118043080A
(zh)
|
2021-08-13 |
2024-05-14 |
昆山新蕴达生物科技有限公司 |
一种基于微管抑制剂的抗体偶联药物
|
CN117881431A
(zh)
|
2021-08-24 |
2024-04-12 |
昆山新蕴达生物科技有限公司 |
一种由可断裂连接子偶联的抗体偶联药物
|
AU2022333323A1
(en)
|
2021-08-27 |
2024-02-29 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
CN118401258A
(zh)
|
2021-12-09 |
2024-07-26 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
WO2024171078A1
(en)
|
2023-02-14 |
2024-08-22 |
H. Lundbeck A/S |
Treatment of opiod-induced pain
|